Axial Spondyloarthritis Market, By Type (Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis), By Therapeutics (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (Meloxicam, Naproxen, Celecoxib, Diclofenac, Others (Indomethacin, etc.)), Biolog

The Global Axial Spondyloarthritis Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.01 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.85% from 2025 to 2032.

Axial Spondyloarthritis (axSpA) represents a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints, characterized by progressive structural damage, functional impairment, and significant impact on patients' quality of life. The global axial spondyloarthritis market encompasses a comprehensive spectrum of therapeutic interventions, diagnostic tools, and management solutions designed to address this debilitating condition that affects millions worldwide. The market includes both ankylosing spondylitis (AS), the radiographic form, and non-radiographic axial spondyloarthritis (nr-axSpA), reflecting the evolving understanding of disease classification and progression. With increasing awareness among healthcare professionals and patients, coupled with advancements in early diagnosis and targeted biologics, the market has witnessed substantial growth momentum.

The therapeutic landscape is dominated by tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, and emerging Janus kinase (JAK) inhibitors, offering patients improved symptom management and disease modification potential. Rising healthcare expenditure, growing prevalence of autoimmune disorders, enhanced diagnostic capabilities through advanced imaging techniques, and robust pharmaceutical research and development activities are collectively driving market expansion, positioning the global axial spondyloarthritis market as a critical segment within the broader rheumatology therapeutics industry.

Market Dynamics

The global axial spondyloarthritis market is propelled by several compelling drivers that collectively enhance market growth prospects and therapeutic advancement opportunities. Increasing disease prevalence, particularly among young adults aged 20-40 years, serves as a primary growth catalyst, with an estimated 0.7% of the global population affected by axSpA, creating substantial demand for effective treatment solutions. Growing awareness and improved diagnostic capabilities through advanced imaging technologies, including magnetic resonance imaging (MRI) and specialized biomarkers, enable earlier disease detection and intervention, expanding the treatable patient population significantly. The robust pipeline of innovative biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) offers enhanced therapeutic efficacy and personalized treatment approaches, driving market expansion through premium pricing and improved patient outcomes.

However, market growth faces notable restraints including high treatment costs associated with biologic therapies, which can exceed USD 50,000 annually per patient, limiting accessibility in price-sensitive markets and creating reimbursement challenges for healthcare systems globally. Stringent regulatory approval processes for new therapeutic agents, coupled with extensive clinical trial requirements, result in prolonged development timelines and increased development costs, potentially hindering market entry for emerging treatments. Additionally, the complex nature of axSpA diagnosis, often involving years of misdiagnosis or delayed diagnosis, creates barriers to timely treatment initiation and market penetration. Nevertheless, significant opportunities emerge through expanding healthcare infrastructure in developing economies, increasing healthcare spending, and growing acceptance of biosimilar medications that offer cost-effective alternatives to branded biologics, potentially democratizing access to advanced treatments and expanding market reach across diverse geographic regions and economic segments.

Key Features of the Study

  • This report provides in-depth analysis of the global axial spondyloarthritis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global axial spondyloarthritis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AbbVie, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, UCB, Eli Lilly and Company, Merck & Co., Gilead Sciences, Sanofi, Takeda, Biogen, and Astellas Pharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global axial spondyloarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global axial spondyloarthritis market
Market Segmentation
  • Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Ankylosing Spondylitis
  • Non-radiographic Axial Spondyloarthritis
  • Therapeutics Insights (Revenue, USD Bn, 2020 - 2032)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Meloxicam
  • Naproxen
  • Celecoxib
  • Diclofenac
  • Others (Indomethacin, etc.)
  • Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
  • TNF inhibitors
  • Adalimumab
  • Infliximab
  • Etanercept
  • Others (Golimumab, etc.)
  • IL-17 inhibitors
  • Secukinumab
  • Ixekizumab
  • Others (Bimekizumab, etc.)
  • JAK inhibitors
  • Tofacitinib
  • Upadacitinib
  • Conventional DMARDs
  • Sulfasalazine
  • Methotrexate
  • Others (Corticosteroids, etc.)
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Subcutaneous (SC) Injections
  • Intravenous (IV) Infusions
  • Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Branded
  • Generic
  • Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Female
  • Male
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Rehabilitation & physiotherapy centers
  • Others (Academic and Research Institutes, etc.)
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
  • Key Players Insights
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Roche
  • UCB
  • Eli Lilly and Company
  • Merck & Co.
  • Gilead Sciences
  • Sanofi
  • Takeda
  • Biogen
  • Astellas Pharma


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Axial Spondyloarthritis Market, By Type
Global Axial Spondyloarthritis Market, By Therapeutics
Global Axial Spondyloarthritis Market, By Route of Administration
Global Axial Spondyloarthritis Market, By Product Type
Global Axial Spondyloarthritis Market, By Gender
Global Axial Spondyloarthritis Market, By Distribution Channel
Global Axial Spondyloarthritis Market, By End User
Global Axial Spondyloarthritis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
Industry Trends
4. Global Axial Spondyloarthritis Market, By Type, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Ankylosing Spondylitis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Non-radiographic Axial Spondyloarthritis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Axial Spondyloarthritis Market, By Therapeutics, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Meloxicam
Naproxen
Celecoxib
Diclofenac
Others (Indomethacin, etc.)
Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
TNF inhibitors
Adalimumab
Infliximab
Etanercept
Others (Golimumab, etc.)
IL-17 inhibitors
Secukinumab
Ixekizumab
Others (Bimekizumab, etc.)
JAK inhibitors
Tofacitinib
Upadacitinib
Conventional DMARDs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Sulfasalazine
Methotrexate
Others (Corticosteroids, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Axial Spondyloarthritis Market, By Route of Administration, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous (SC) Injections
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intravenous (IV) Infusions
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Axial Spondyloarthritis Market, By Product Type, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Branded
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Axial Spondyloarthritis Market, By Gender, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Female
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Male
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Axial Spondyloarthritis Market, By End User, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Surgical Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rehabilitation & physiotherapy centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Academic and Research Institutes, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Axial Spondyloarthritis Market, By Region, 2020 - 2032, Value (USD Bn)
Introduction
Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
South Africa
North Africa
Central Africa
12. Competitive Landscape
AbbVie
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Amgen
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Janssen Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Roche
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
UCB
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Gilead Sciences
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Takeda
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Biogen
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Astellas Pharma
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
13. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
14. References and Research Methodology
References
Research Methodology
About us
*Browse 32 market data tables and 28 figures on ‘Axial Spondyloarthritis Market' - Global forecast to 2032

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings